INTRODUCTION Decisions regarding adjuvant chemotherapy in women with oestrogen receptor positive, human epidermal growth factor receptor 2 negative, node negative, early invasive breast cancer are unclear. The Recurrence Score ® (RS) from Oncotype DX ® (ODX) testing guides decisions based on individual cancer genomics. The aim of this study was to evaluate the impact of introducing ODX results on adjuvant treatment decisions and its potential economic benefits. METHODS Patients offered the test were identified from the ODX requesting system. Information on reasons behind chemotherapy treatment decisions were collected from clinical letters and the pathology system. The Nottingham prognostic index (NPI) scores were calculated for each individual patient. RESULTS A total of 101 patients were identified as having undergone ODX testing over 21 months. The median age was 57 years (range: 41-72 years), the median NPI was 3.70 (range: 3.40-5.26) and the median RS was 17 (range: 0-59). NPI did not predict the risk category. All of the patients in the high risk group, 35.1% in the intermediate risk group and 5.4% in the low risk group received chemotherapy. The majority of low risk patients who received chemotherapy made a decision prior to the ODX result. CONCLUSIONS In our unit, RS aided our decision making regarding adjuvant chemotherapy. Patients with a higher RS were more likely to receive chemotherapy. If NPI had been used alone, more women would have been offered chemotherapy. Good communication with patients prior to testing is important to ensure it is cost effective.
Breast cancer (BC) is the most common cancer in the UK with around 55,000 new cases diagnosed every year. 1 In 2016 there were over 11,000 deaths from BC, accounting for 7% of all cancer deaths. Approximately 70% of those who die have oestrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative cancers. 2, 3 Decisions regarding the use of adjuvant chemotherapy in patients with ER positive, HER2 negative, lymph node negative (N0 or N1mi), early invasive BC are unclear. Traditionally, clinical and pathological characteristics have been used alone to aid adjuvant treatment decisions. Not all patients will benefit from chemotherapy, and many patients are therefore at risk of side effects in addition to the economic and personal financial impact of receiving chemotherapy with minimal clinical benefit. Oncotype DX ® (ODX) is a test developed by Genomic Health (Redwood City, CA, US) based on individualised cancer genomics to help predict which patients would benefit most from chemotherapy.
ODX is a gene expression profiling test that quantifies the expression of certain genes in BC tissue using reverse transcription polymerase chain reaction. A formalin fixed, paraffin embedded tissue sample is sent to the centralised laboratory in the US for testing and the result is usually available within two weeks.
There are a total of 21 genes that are assayed. These comprise 5 reference genes (ACTB, GAPDH, RPLP0, GUSB, TFRC) and 16 cancer related genes. The cancer genes include genes that code for HER2 (GRB7, HER2), oestrogen (ER, PGR, BCL2, SCUBE2), proliferation (MKI67, STK15, BIRC5, CCNB1, MYBL2) and invasion (MMP11, CTSL2) as well as GSTM1, CD68 and BAG1. An algorithm is used to provide a Recurrence Score ® (RS) from 0 to 100, with higher scores correlating to a greater likelihood of recurrence within ten years. 4 The RS is stratified into three risk groups: low risk (RS <18), intermediate risk (RS 18-30) and high risk (RS >30). ODX has been validated by a number of large studies and has been shown to alter clinical decisions on adjuvant treatment in up to 30% of cases. 5 Patients in the low RS group do not benefit from chemotherapy in addition to hormone therapy whereas patients in the high risk group show the most benefit. RS predicts chemotherapy benefit independently from traditional clinicopathological characteristics. 6 The benefit of chemotherapy in the intermediate risk group is less clear. TAILORx (Trial Assigning IndividuaLized Options for Treatment) is an ongoing trial investigating this patient group further; it has yet to report.
Patients with a RS of 11-25 are randomised to either hormonal therapy alone or chemotherapy in addition to hormonal therapy. 7 The ODX test is now incorporated into all major BC guidelines, [8] [9] [10] [11] including National Institute for Health and Care Excellence (NICE) guidance. 12 It has also been deemed by NICE as a quality standard of care for patients with ER positive, HER2 negative BC with an intermediate risk of recurrence (Nottingham prognostic index [NPI] >3.4). 13 ODX testing has been available in the National Health Service (NHS) since 2015 and has been routinely requested for NHS patients in our trust since October 2015. This retrospective study evaluated the introduction of ODX testing in our breast unit (including whether patients' RS correlated with the uptake of adjuvant chemotherapy). The aim was to make an assessment of the impact of ODX results in terms of numbers of patients receiving chemotherapy and whether it is cost effective.
Methods
All patients who had undergone ODX testing since its routine introduction in clinical practice in October 2015 were identified retrospectively using the ODX requesting programme. Inclusion criteria comprised patients with ER positive, HER2 negative, N0 or N1mi BC with a NPI of 3.4-5.4. At the time of the study, NPI 3.4-5.4 was the inclusion criterion for ODX testing but this has more recently changed to NPI >3.4. 13, 14 Patients were excluded if they were not treated on the NHS, there was not enough tissue sample available for the test to be performed or if they had received neoadjuvant treatment. In cases with bilateral disease, the tumour with the worst prognosis was included in the study. Patients with previous BC were only included if the tumour represented new primary disease. Further data were then collected via electronic case note review and NPI scores were calculated. Oncology case notes were also reviewed to identify factors influencing decisions regarding chemotherapy.
All patients in the breast unit had their results discussed at a multidisciplinary team meeting, where the decision for offering adjuvant treatment was made. A member of the multidisciplinary team discussed the ODX test with patients and counselled them prior to requesting the test. All patients received hormone treatment. No clinical decisions were made regarding adjuvant treatment prior to knowledge of the ODX results.
In order to identify which patients would have been offered chemotherapy in addition to hormone therapy prior to the availability of ODX testing, an online prognostication and treatment benefit tool (PREDICT V2.0, https://predict. nhs.uk/predict_v2.0.html) was used to calculate the expected ten-year survival advantage with chemotherapy. A patient would have been offered chemotherapy without ODX testing if they met any of the following criteria: tumour size ≥4cm, grade 3, age ≤50 years or >5% PREDICT benefit of chemotherapy.
Patient demographics, pathological factors and reasons for adjuvant therapy uptake in the study cohort were examined. Differences of means were detected using analysis of variance (ANOVA) with a p-value of <0.05 considered statistically significant.
The cost of chemotherapy for patients with BC including administration, drug costs and the costs of adverse effects has been calculated as £7,728. 15 The manufacturer's cost for the ODX test is £2,580 although it is available to the NHS at a reduced undisclosed price. 14 These figures were used for cost analysis based on the numbers of patients who would have been offered chemotherapy previously minus those receiving chemotherapy in addition to the costs of ODX testing for all patients.
Results
Routine ODX testing at our trust started in October 2015.
In the following 21 months, 113 patients underwent testing. Of these, 12 patients were excluded (7 private patients, 2 HER2 positive or equivalent, 1 ER negative, 1 node positive and 1 with not enough tissue sample available), leaving 101 eligible patients for the study.
The patient demographics are shown in Table 1 . The mean patient age was 56.8 years with a median of 57 years Table 2 shows the characteristics of each of these groups. A one-way ANOVA test was used to examine the differences between the NPI means for the three risk groups. There was no statistically significant difference between the groups (p=0.22). 
Chemotherapy uptake

Reasons for chemotherapy decisions
In the low risk group, three patients received chemotherapy. For one, this was based on clinical factors (age ≤50 years and tumour size ≥4cm) and the other two patients had already decided that they wished to pursue chemotherapy regardless of the ODX results. In the intermediate risk 
Treatment costs
For the 61 patients who would have been offered chemotherapy prior to the introduction of ODX testing, the total potential cost was estimated at £471,408. This was based on a chemotherapy cost per patient (including adverse effect costs) of £7,728. 15 The manufacturer's cost for the ODX test is £2,580.
14 For all 101 patients to undergo testing and 24 patients to receive chemotherapy, the total cost was estimated to be £446,052 with a potential saving of £25,356 over the 21 months of the study period.
Discussion
This study demonstrates that ODX results enabled patients to be identified who would potentially benefit from chemotherapy but who would not otherwise have been offered this treatment. Management decisions were changed as a result of ODX testing in almost half of the patients in our study. Overall, fewer patients received chemotherapy and this has demonstrated cost effectiveness. Following meta-analysis of 4,156 patients, Carlson and Roth reported the proportions of patients falling into each RS group as 48.8% in the low, 39.0% in the intermediate and 12.2% in the high risk group. 5 This is similar to our study, with 55.4%, 36.6% and 7.9% respectively. Their meta-analysis showed the uptake of chemotherapy was 5.8% in the low, 37.4% in the intermediate and 83.4% in the high risk group. Our results were again similar, with 5.4%, 35.1% 100% uptake of chemotherapy respectively. Our patient cohort is therefore likely to be representative of the general population undergoing ODX testing.
Carlson and Roth also reported that patients in the low risk group were more likely to follow the treatment suggested by the ODX results than those with a high RS. 5 In our study, 100% of patients in the high RS group followed the recommended treatment compared with 94.6% in the low RS group. Although this is not a statistically significant difference, it is reassuring that the majority of patients are following recommended treatment.
Of patients undergoing chemotherapy in the low risk group, one was aged ≤50 years with a tumour measuring ≥4cm and two had already made a decision prior to receiving the ODX results that they wished to proceed with chemotherapy regardless of their RS. The majority of the patients in the intermediate risk group made a decision to undergo chemotherapy based on their RS being in the top half of the group and/or adverse clinical or pathological factors. In a study of oncologists in the US, a third were not regularly discussing prior preference for chemotherapy when counselling patients about ODX testing. 16 Counselling of patients prior to testing needs to occur to circumvent situations where patients have already made up their mind on adjuvant therapy decisions in order to avoid the unnecessary costs of testing and to ensure patients are assisted in making an informed decision. Decisions regarding chemotherapy were changed because of ODX results in 49.5% of patients, with 45.5% being spared chemotherapy. The literature reports that approximately a third of patients have a change to their adjuvant therapy management plan due to ODX results. 5 Our study has a higher rate than other published papers. As our uptake of chemotherapy in each RS group was similar to that in the literature, this may be due to an overestimate of the proportion of patients who would have been offered chemotherapy.
Our study has demonstrated potential savings of over £25,000 for the trust. Owing to the retrospective nature of the study, it is possible that the proportion of patients who would have been offered chemotherapy prior to the introduction of ODX testing has been misjudged and the number of patients who may have refused adjuvant treatment could not be taken into account. Up to 19% of patients have been reported to refuse chemotherapy despite survival benefits. 17 On the other hand, the potential savings figure is likely to be an underestimate as the manufacturing price on which the figure is based is higher than the undisclosed price paid by the NHS. In addition to financial savings, there are also savings to the individual in terms of the adverse effects of chemotherapy on quality of life and financial income. As a consequence, there would be a reduction in the economic burden of patients undergoing chemotherapy. Two other studies with similar numbers of ER positive, HER2 negative, N0 patients have also shown a financial benefit of the introduction of ODX testing in the NHS. 18, 19 
Study limitations
The main limitation of this study is its retrospective nature. The potential uptake of chemotherapy in these patients may therefore not reflect fully the adjuvant treatment decisions that would have been made had ODX testing not occurred. There are no reliable follow-up data available yet for this cohort of patients as ODX was only introduced approximately two years prior to the end of the study period, and more time is required for accurate recurrence and survival rates.
Conclusions
This study has demonstrated successful introduction of ODX testing at a large NHS trust breast unit and excellent uptake with a subsequent reduction in chemotherapy that reflects that of the published literature for patients with ER positive, HER2 negative, early invasive BC. Our study has added to the current literature by investigating reasons for chemotherapy uptake in the low and intermediate RS groups. Patients need to be counselled appropriately prior to offering the ODX test in order to avoid patients making adjuvant treatment decisions that are not guided by ODX results. Our study has shown an overall cost benefit to ODX testing in addition to probable improved individual quality of life but more studies including follow-up data are required to investigate further.
